哮喘和慢性阻塞性肺疾病(COPD)是最常見的呼吸道疾病之一,全球分別有3 億和2.1 億患者。肺部吸入給藥是治療和管理哮喘、COPD 等呼吸道疾病的首選給藥方式,而患者的依從性與該類制劑的療效優(yōu)劣有密切關(guān)系。綜述現(xiàn)在已經(jīng)上市的肺部吸入給藥治療哮喘和慢性阻塞性肺疾病的主要劑型和藥品,以及霧化吸入劑、定量吸入劑和干粉吸入劑對患者依從性的影響,并認(rèn)為提高患者依從性需要反復(fù)提供給患者個性化用藥和正確使用給藥裝置的指導(dǎo)。

Asthma and chronic obstructive pulmonary disease (COPD) are common respiratory diseases. Globally, 300 million people suffer from asthma and 210 million people from COPD respectively. Pulmonary drug delivery is the preferred administration mode for the treatment and management of pulmonary diseases, such as asthma and COPD, and adherence has closely relationship with the efficacy of this inhaler therapy. The main inhalers and inhaler medicines of pulmonary drug delivery available in the marketplace, and the impact of nebulizers, metered-dose inhalers, and dry powder inhalers on the adherence are reviewed. Promoting adherence involves a provision of guidance for personalized administration and right use of pulmonary drug delivery system are concluded.